- Bundesärztekammer (BÄK): Grundsätze der Bundesärztekammer zur ärztlichen Sterbebegleitung Präambel. Deutsches Ärzteblatt 2011; 108 (7): A346–8.
- Bundesärztekammer (BÄK): Stellungnahme der Bundesärztekammer „Medizinische Indikationsstellung und Ökonomisierung“. d.aerzteblatt.de/BS61 (last accessed on 14. September 2015).
- Bundesgerichtshof (BGH): AZ XII ZB 2/03. N Jurist Wochenschr 2003; 56: 1588–94.
- Raspe H: Ethische Aspekte der Indikation. In: Toellner R, Wiesing U (eds): Wissen – Handeln – Ethik. Strukturen ärztlichen Handelns und ihre ethische Relevanz. Stuttgart Jena New York: G. Fischer 1995; 21–36.
- Sahm S: Autonomie, ärztliche Indikation und Entscheidungsfindung. In: Charbonnier R, Dörner K, Simon S (eds): Medizinische Indikation und Patientenwille. Stuttgart New York: Schattauer 2008; 21–131.
- Winkler E: Ist ein Therapieverzicht gegen den Willen des Patienten ethisch begründbar? Ethik Med 2010; 22: 89–102.
- Alt-Epping B, Nauck F: Der Wunsch des Patienten – ein eigenständiger normativer Faktor in der klinischen Therapieentscheidung? Ethik Med 2012; 24 (1): 19–28.
- Raijmakers, NJH, et al.: Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects. Annals of Oncology 2011; 22(7): 1478–86.
- Bruera E, et al.: Parenteral hydration in patients with advanced cancer: a multicenter, doubleblind, placebo-controlled randomized trial. J Clin Oncol 2013; 31 (1): 111–8.
- Nakajima N, Hata Y, Kusumuto K: A clinical study on the influence of hydration volume on the signs of terminally ill cancer patients with abdominal malignancies. J Palliat Med 2013; 16 (2): 185–9.
- Breuer B, Fleishman S, Cruciani R, Portenoy R: Medical oncologists’ attitudes and practice in cancer pain management: a national survey. J Clin Oncol 2011; 29 (36): 4769–75.
- Deandrea S, Montanari M, Moja L, et al.: Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008; 19 (12): 1985–91.
- Sabatowski R, Arens E R, Waap I, Radbruch L: Tumorschmerztherapie in Deutschland: Ergebnisse und Analysen einer Befragung von Ärzten. Schmerz 2001; 15 (4): 241–7.
- Sapir R, Catane R, Strauss-Liviatan N, Cherny N: Cancer Pain: Knowledge and attitudes of physicians in Israel. J Pain Symptom Manage 1999; 17 (4): 266–76.
- Von Roenn JH, Cleeland CS, Gonin R, Hatfield AK, Pandya KJ: Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med 1993; 119 (2): 121–6.
- Alt-Epping B, Bauer J, Nauck F, Schuler U, Strohscheer I: Schmerztherapie in der Onkologie – eine bundesweite Umfrage unter der Schirmherrschaft der Deutschen Gesellschaft für Hämatologie/Onkologie. Schmerz 2014; 28: 157–165. DOI: 10.1007/s00482–014–1412–8.
- Abernethy AP, et al.: Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. British Medical Journal 2003; 327 (7414): 523–6.
- Jennings AL, et al.: Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev 2001; (4): CD002066.
- Johnson MJ, et al.: Morphine for the relief of breathlessness in patients with chronic heart failure – A pilot study. European journal of heart failure 2002; 4 (6): 753–6.
- Mazzocato C, Buclin T, Rapin CH: The effects of morphine on dyspnea and ventilator function in elderly patients with advanced cancer: A randomized double-blind controlled trial. Ann Oncol 1999; 10 (12): 1511–4.
- Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 1.0, 2015, AWMF-Registernummer: 128/001OL. leitlinienprogrammonkologie. de/Palliativmedi zin.80.0.html (last accessed on 29. August 2015).
- Bakitas MA, Tosteson TD, Li Z, et al.: Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 2015; 33 (13): 1438–45.
- Johnsen AT, Petersen MA, Gluud C, et al.: Detailed statistical analysis plan for the Danish Palliative Care Trial (DanPaCT). Trials 2014; 26 (15): 376.
- Zimmermann C: Early palliative care for patients with advanced cancer: a clusterrandomised controlled trial. Lancet 2014; 383 (9930): 1721–30.
- Temel J, Greer J, Muzikansky A, et al.: Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733–42.
- Gómez-Batiste X, Martínez-Muñoz M, Blay C, et al.: Prevalence and characteristics of patients with advanced chronic conditions in need of palliative care in the general population: A cross-sectional study. Palliat Med 2014; 28: 302.
- Ostgathe C, Alt-Epping B, Golla H, Gaertner J, Lindena G, Radbruch L, Voltz R and the Hospice and Palliative Care Evaluation (HOPE) Working Group in Germany: Noncancer patients in specialised palliative care in Germany: What are the problems? Palliat Med 2011; 25: 148–52.
- Alt-Epping B, Geyer A, Nauck F: Palliativmedizinische Konzepte bei nicht-onkologischen Grunderkrankungen. Dtsch Med Wschr 2008; 133: 1745–9.
- Bee PE, Barnes P, Luker KA: A systematic review of informal caregivers’ needs in providing home-based end-of-life care to people with cancer. Journal of Clinical Nursing 2009; 18 (10): 1379–93.
- Docherty A, Owens A, Asadi-Lari M, Petchey R, Williams J, Carter YH: Knowledge and information needs of informal caregivers in palliative care: a qualitative systematic review. Palliat Med 2008; 22 (2): 153–71.
- Moss AH, Lunney JR, Culp S, et al.: Prognostic significance of the „surprise“ question in cancer patients. J Palliat Med 2010; 13 (7): 837–40. 32. Murray SA, Boyd K, Sheikh A: Palliative care in chronic illness. BMJ 2005; 330 (7492): 611–2.
- Murray SA, Boyd K, Sheikh A: Palliative care in chronic illness. BMJ 2005; 330 (7492): 611–2.
- Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P: Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011; (1): CD003448.
- Schulz C: Interventionen bei Kernsymptomen – Angst. In: Fegg M, Gramm J, Pestinger M (eds): Psychologie und Palliative Care. Stuttgart: Kohlhammer 2012; 191–7.
- Schnipper LE, Smith TJ, Raghavan D, et al.: American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012; 30 (14): 1715–24.
- Dodson JA, Fried TR, Van Ness PH, Goldstein NE, Lampert R. Patient preferences for deactivation of implantable cardioverterdefibrillators. JAMA Intern Med 2013; 173 (5): 377–9.
- Carlsson J, Paul NW, Dann M, Neuzner J, Pfeiffer D: The deactivation of implantable cardioverter-defibrillators: medical, ethical, practical, and legal considerations. Dtsch Arztebl Int 2012; 109 (33–34): 535–41.
- Fromme EK, Stewart TL, Jeppesen M, Tolle SW: Adverse experiences with implantable defibrillators in Oregon hospices. Am J Hosp Palliat Care 2011; 28 (5): 304–9.
- Lampert R, Hayes DL, Annas GJ, et al.: HRS Expert Consensus Statement on the management of cardiovascular implantable electronic devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm 2010; 7 (7): 1008–26.
- Padeletti L, et al.: EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace 2010; 12 (10): 1480–9.
- Whellan DJ, Goodlin SJ, Dickinson MG, et al.: Quality of Care Committee, Heart Failure Society of America. End-of-life care in patients with heart failure. J Card Fail 2014; 20 (2): 121–34.
- McMurray JJ, Adamopoulos S, Anker SD, et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart Journal 2012; 33: 1787–1847.
- Neitzke G: Unterscheidung zwischen medizinischer und ärztlicher Indikation. In: Charbonnier R, Dörner K, Simon S (Hrsg) Medizinische Indikation und Patientenwille. Stuttgart, New York: Schattauer 2008; 53–66.